Screener / SEC EDGAR /CIK 0001821825 /10-K filed Feb 24, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Organon & Co. OGN

Compare with peers Embed
SEC comment letters, last 20 years

3 reviews of OGN's filings by SEC staff

UPLOAD and CORRESP
Reviews 3 latest letter Apr 30, 2024
Questions asked 26 each answered in the company's own letter
No closing letter 2 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 26 numbered comments
  3. 3. Company replies 2 CORRESP
  4. 4. Reviews closed 1 of 3 closing letter

Half the closed reviews took 56 days or less from the first letter to the closing letter.

Form 10-K

2024-04-30 to 2024-06-25 · 6 questions · 2 letters from the SEC, 2 from the company
Review closed 2024-06-25
Non-GAAP measuresResults discussion (MD&A)Income taxes
Exhibit 99.1 · Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023, page 1
SEC asked (1)
Within the header of your earnings release you discuss the non-GAAP measure Adjusted EBITDA without also discussing the most comparable GAAP measure of net income. This presentation gives greater prominence to the non-GAAP measure and does not comply with Item 10(e)(1)(i)(A) of Regulation S-K. Please revise your header and presentations in future filings accordingly.
Rest of the question

Refer to Question 102.10(a) of the Division's Compliance & Disclosure Interpretations (“C&DIs”) on Non-GAAP Financial Measures.

OGN answered
The Company respectfully acknowledges the Staff’s comment and will revise in future filings the headers of presentations, press releases, and Commission filings to discuss the most directly comparable GAAP measure before the related non-GAAP measure. In addition, the Company respectfully advises the Staff that it has already reflected the foregoing in its earnings press release, dated May 2, 2024 for the first quarter ended March 31, 2024.
Read in the reply
In its next report

First report after the company's reply of May 14, 2024: 10-Q filed Aug 7, 2024 ↗, against the 10-Q filed Nov 3, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Table 4. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information, page 14
SEC asked (2)
We note your non-GAAP reconciliation tables presented here and on page15 give the appearance of a full non-GAAP income statement. Please note that the presentation of a full non-GAAP income statement, or a presentation that gives the appearance of one, may place undue prominence on the non-GAAP information and give the impression that the non-GAAP income statement represents a comprehensive basis of accounting.
Rest of the question

Please remove this presentation in your future filings. To the extent you wish to present any of the non-GAAP measures, you could present a separate reconciliation for each non-GAAP measure and provide all the disclosures required by Item 10(e)(1)(i) of Regulation S-K including quantification and description of each adjustment individually. Refer to Question 102.10(a) and (c) of the C&DIs for Non-GAAP Financial Measures.

OGN answered
The Company respectfully acknowledges the Staff’s comment and will revise in future filings the presentation of the non-GAAP reconciliation tables to provide a separate reconciliation for each non-GAAP measure in accordance with the Staff’s comment. In addition, the Company respectfully advises the Staff that it has already reflected the foregoing in Table 4 of its earnings press release, dated May 2, 2024 for the first quarter ended March 31, 2024.
Read in the reply
In its next report

First report after the company's reply of May 14, 2024: 10-Q filed Aug 7, 2024 ↗, against the 10-Q filed Nov 3, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Table 4. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information, page 14
SEC asked (3)
We note that table 4 presents the tax impact of your non-GAAP adjustments. Please revise future filings to provide a brief explanation as to how the tax impact of the non-GAAP adjustments were computed. Refer to Question 102.11 of the C&DIs for Non- GAAP Financial Measures.
OGN answered
The Company respectfully acknowledges the Staff’s comment and will revise in future filings the presentation of the non-GAAP reconciliation tables to provide a brief explanation as to how the tax impact of the non-GAAP adjustments were computed, such as “Represents the estimated tax impacts on the reconciling items by applying the statutory rate and applicable law of the originating territory of the non-GAAP adjustments.” In addition, the Company respectfully advises the Staff that it has already reflected the foregoing in Table 4 of its earnings press release, dated May 2, 2024 for the first
Rest of the answer

quarter ended March 31, 2024.

Read in the reply
In its next report

First report after the company's reply of May 14, 2024: 10-Q filed Aug 7, 2024 ↗, against the 10-Q filed Nov 3, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Table 5. Reconciliation of GAAP Income Before Income Taxes to Adjusted EBITDA, page 16
SEC asked (4)
We note that you present Adjusted EBITDA as a non-GAAP performance measure. However, your reconciliation does not reconcile Adjusted EBITDA to the most directly comparable GAAP measure, net income (loss), as required by Item 10(e)(1)(i)(B) of Regulation S-K. Please revise your presentation in future filings accordingly. Refer also to Question 103.02 of the C&DIs for Non-GAAP Financial Measures.
OGN answered
The Company respectfully acknowledges the Staff’s comment and will revise in future filings the presentation of the reconciliation to Adjusted EBITDA to reconcile Adjusted EBITDA to net income (loss). In addition, the Company respectfully advises the Staff that it has already reflected the foregoing in Table 5 of its earnings press release, dated May 2, 2024 for the first quarter ended March 31, 2024.
Read in the reply
In its next report

First report after the company's reply of May 14, 2024: 10-Q filed Aug 7, 2024 ↗, against the 10-Q filed Nov 3, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Table 5. Reconciliation of GAAP Income Before Income Taxes to Adjusted EBITDA, page 16
SEC asked (5)
Please refer to footnote (2) and “one-time costs.” Please tell us and revise your future filings to quantify and describe the nature of each of the significant components of these adjustments. Explain to us how each of these one-time costs comply with the guidance of Questions 100.01 and 102.03 of the C&DIs for Non-GAAP Financial Measures.
OGN answered
The Company respectfully acknowledges the Staff's comment and advises the Staff that in future filings with the Commission it will clearly quantify and describe the nature of each significant component of the adjustments. When considering whether to reflect these expenses as adjustments to our non-GAAP financial measures, we considered Question 100.01 and Question 102.03 of the Staff’s C&DI on Non-GAAP Financial Measures.

We believe that excluding the impact of these adjustments from the Company’s results of operations as part of an earnings release furnished as an exhibit to the Company’s
Rest of the answer

Current Reports on Form 8-K provides information meaningful to investors and analysts and provides better visibility to evaluate period-over-period comparisons of the Company's ongoing business. The Company notes that it has not included, nor plans to include, non-GAAP financial measures within its Form 10-K. We have described below the nature of these adjustments, which have also been presented in the first quarter 2024 earnings release attached as Exhibit 99.1 to the Company’s Form 8-K, filed on May 2, 2024.

The spin-related costs and manufacturing network related costs are related to the separation from Merck & Co., Inc., Rahway, NJ, US (“Merck”) in June 2021. The Company’s separation from Merck is, by the nature of the transaction, an unusual and infrequent event. These costs are incremental or redundant costs that are a direct result of this transaction and are not indicative of Organon’s ongoing operations as a separate, stand-alone company and vary in amounts and frequency. These costs include:

Costs related to the separation and establishment of Organon’s information systems and temporary transition service agreements – From the time of the 2021 separation from Merck, Organon has had to utilize certain information systems of Merck, including its enterprise resource planning system. As part of the separation arrangements with Merck, the Company is transitioning and establishing its own stand-alone information systems by the end of 2024. While a standard implementation of an enterprise resource planning system may generally take approximately 5-10 years, as part of the separation, Organon is implementing its stand-alone enterprise resource planning system within approximately three years. In order to adhere to the timeline, the Company incurred significant incremental costs, which are not representative of the Company’s normal, recurring operations. These costs primarily include redundant software licensing costs associated with licenses to access Merck systems under the temporary transition services agreements, and incremental third-party consulting costs to implement the Company’s stand-alone information systems. These costs will be substantially completed by the end of 2024. Software licensing costs related to Organon’s stand-alone systems are presented as normal, recurring operating expenses incurred in the ordinary course of the Company’s business operations (for which the Company does not adjust any of its financial measures).

Costs related to exiting manufacturing and supply agreements with Merck – These are additional costs related to disentanglement activities at manufacturing facilities that are necessary to bifurcate Organon’s operations from the Merck manufacturing network, thereby resulting in Organon incurring incremental separation and transition costs. These costs include incremental technology transfer costs, stability studies and qualification test costs, which are required in order to separate from the Merck manufacturing network, as well as incremental third-party contractor fees related to these activities. In addition, these costs also reflect an incremental non-cash charge of accelerated depreciation of fixed assets which are solely used to manufacture Merck products.

Based on the foregoing, the non-GAAP financial measures we have historically presented reflect adjustments based on the exclusion of the following items:

Spin-related costs: The Company has excluded certain costs incurred in connection with activities taken to separate the Company from Merck. While the spin-related costs have been incurred in multiple periods, this is due to the inherent time and complexity to disentangle from Merck. These costs include information technology infrastructure, primarily related to the implementation of a stand-alone enterprise resource planning system, redundant software licensing costs associated with licenses to access Merck systems under the temporary transition services agreements, and incremental third-party consulting costs to implement the Company’s stand-alone information systems. As such, we do not consider these costs to be part of normal operations. For the three months ended March 31, 2024, costs for information technology infrastructure, primarily related to the implementation of a stand-alone enterprise resource planning system and redundant software licensing costs, were $21 million and costs for redundant temporary transition service agreements with Merck were $14 million. For the year ended December 31, 2023, costs for information technology infrastructure, primarily related to the implementation of a stand-alone enterprise resource planning system and redundant software licensing costs, were $134 million and costs for temporary transition service agreements with Merck were $28 million.

Manufacturing network related costs: The Company has excluded certain costs associated with the exiting of temporary manufacturing and supply agreements with Merck. These costs include accelerated depreciation, exit premiums, incremental technology transfer costs, stability studies and qualification batch costs, and third-party contractor costs related to these activities. For the three months ended March 31, 2024, manufacturing network related costs were $10 million. There were no manufacturing related costs for the year ended December 31, 2023.

Other costs: The Company has excluded certain other costs related to inventory step-up adjustments from a business development transaction, intangible asset impairments, and legal settlement charges.

Inventory step-up adjustments represent a non-cash adjustment to the valuation of inventory acquired as part of a business development transaction. These purchase accounting related adjustments are incremental and infrequent costs to the Company’s operations, which are generally recognized over a period of approximately six to twelve months. There were no inventory step-up adjustments for the three months ended March 31, 2024. For the year ended December 31, 2023, inventory step-up adjustments were $2 million.

Impairments represent a non-cash adjustment to the value of an intangible asset. These are unusual charges and vary in both the amount and frequency. There were no intangible asset impairments in the three months ended March 31, 2024 or the year ended December 31, 2023.

Legal settlement charges represent the significant reserves for, or settlement of, legal matters. Legal settlements have been infrequent and outside the ordinary course of our operations and are separate and distinct from normal, recurring legal expenses, such as ongoing legal defense costs, which are incurred in the ordinary course of the Company’s business operations for which the Company does not adjust any of its financial measures. There were no legal settlement charges for the three months ended March 31, 2024. For the year ended December 31, 2023, legal settlement charges were $82 million.

As described above, the Company believes these adjustments are appropriate, and based on the guidance in Question 100.01 and Question 102.03 of the Staff's C&DI on Non-GAAP Financial Measures, have been excluded because they are related to infrequent, unusual, and/or non-recurring matters. We believe the exclusion of these items is appropriate as it provides additional meaningful information to investors about certain adjustments that are not indicative of our ongoing operations, are not misleading, and would affect the comparability of our operating results. In addition, the Company respectfully advises the Staff that it has already provided a description of the nature of the significant components of these adjustments and quantified the amounts in Table 5 of its earnings press release, dated May 2, 2024 for the first quarter ended March 31, 2024. The Company advises the Staff that in future filings with the Commission we will rename the caption of “one-time costs” to three separate line items for “Spin Related Costs”, “Manufacturing Network Related Costs” and “Other Costs”. Footnote disclosure will be provided to further describe and quantify the components of the adjustments in future filings.

*******

The Company appreciates the efforts of the Staff in reviewing our response to the Comment Letter. We are fully committed to working with the Commission to respond to your comments and to provide you with all the information you require. Accordingly, should you have any questions regarding the Company’s response to your comments, please contact Matthew Walsh at 551-430-6000.

Read in the reply
In its next report

First report after the company's reply of May 14, 2024: 10-Q filed Aug 7, 2024 ↗, against the 10-Q filed Nov 3, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibits
SEC asked
We note your response to prior comment 2 and the updated presentation included within Table 4 of Exhibit 99.1 from the Form 8-K dated May 2, 2024. However, the updated presentation continues to include most of the line items and subtotals found in your GAAP income statement and adds a measure of gross profit not found in your Form 10-Q.
Rest of the question

As previously requested, please remove this presentation from future filings or alternatively explain to us in detail how this presentation complies with the guidance in Question 102.10(a) and (c) of the C&DIs for Non-GAAP Financial Measures.

OGN answered
The Company respectfully acknowledges the Staff’s comment. The Company intends to include a measure of gross profit in the GAAP Consolidated Statements of Income in its future Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.

In addition, the Company will revise its presentation of the information in the referenced Table 4 in future filings to present separately each non-GAAP reconciliation, so that, consistent with the guidance in Question 102.10(c), the presentation does not include most of the line items and subtotals found in a GAAP income statement.
Rest of the answer

The following reflects this proposed presentation as if it had been applied to the information set forth in Table 4 of the earnings release that was furnished as an exhibit to the May Form 8-K.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Metrics

(Unaudited, $ in millions except per share)

Three months ended,

March 31, 2024 March 31, 2023

GAAP Gross Profit $ 957 $ 958

Adjusted for:

Spin-related costs (1)

3 10

Manufacturing network costs (2)

Stock-based compensation 4 4

Amortization 33 29

Other - 2

Adjusted Non-GAAP Gross Profit $ 1,007 $ 1,003

(1) Spin-related costs include costs from the separation of Merck & Co., Inc., Rahway, NJ, US.

(2) Manufacturing network related costs include costs from exiting manufacturing and supply agreements with Merck & Co., Inc., Rahway NJ, US.

GAAP Gross Margin 59.0 % 62.3 %

Total impact of Non-GAAP adjustments 3.1 % 2.9 %

Adjusted Non-GAAP Gross Margin 62.1 % 65.2 %

GAAP Selling, general and administrative expenses $ 431 $ 435

(40) (46)

Stock-based compensation (18) (15)

Other - (1)

Adjusted Non-GAAP Selling, general and administrative expenses $ 373 $ 373

GAAP Research and development expenses $ 112 $ 129

(2) (3)

Stock-based compensation (4) (3)

Adjusted Non-GAAP Research and development expenses $ 106 $ 123

Reconciliation of GAAP Reported to Non-GAAP Adjusted Metrics (Continued)

GAAP Reported Net Income $ 201 $ 177

Cost of sales adjustments 50 45

Selling, general and administrative adjustments 58 62

Research and development adjustments 6 6

Restructuring 23 4

Other 4 6

Tax impact on adjustments above(1)

(27) (24)

Non-GAAP Adjusted Net Income $ 315 $ 276

(1) Represents the estimated tax impacts on the reconciling items by applying the statutory rate and applicable law of the originating territory of the non-GAAP adjustments.

GAAP Diluted Earnings per Share $ 0.78 $ 0.69

Total impact of Non-GAAP adjustments $ 0.44 $ 0.39

Non-GAAP Diluted Earnings per Share $ 1.22 $ 1.08

As previously discussed in our response dated May 14, 2024 to Comment 5, the Company will provide a further description and quantification of the spin-related and manufacturing network costs within the footnotes of our earnings releases.

*******

The Company appreciates the efforts of the Staff in reviewing our response to the Comment Letter. We are fully committed to working with the Commission to respond to your comments and to provide you with all the information you require. Accordingly, should you have any questions regarding the Company’s response to your comments, please contact Matthew Walsh at 551-430-6000.

Read in the reply

Also in this review: closing letter, 2024-06-25

Form 10-12B

2021-03-24 to 2021-04-20 · 4 questions · 2 letters from the SEC, 0 from the company
No closing letter
InventoryAcquisitions
SEC letter of Mar 24, 2021 ↗ no reply letter on EDGAR
Item 15. Financial Statements and Exhibits, page 4
SEC asked (1)
We note you have redacted certain information from Exhibit 10.12. To the extent you have redacted such information pursuant to Item 601(b)(10)(iv) of Regulation S-K, please mark the exhibit index to indicate that portions of the exhibit have been omitted because it is both not material and would likely cause competitive harm to the company if publicly disclosed.
OGN answered

No reply letter found.

Adjustment (h), page 48
SEC asked (2)
You disclose that Organon expects to have approximately $500 million of cash following the completion of the Separation. Please revise to clarify how you expect to end up with this cash balance. For example, if this balance takes into account the $9.5 billion of borrowings expected to be incurred in connection with the Separation, net of the $9.0 billion expected to be distributed to Merck, please disclose this fact.
OGN answered

No reply letter found.

Notes to the Unaudited Pro Forma Information · Adjustment (c), page 48
SEC asked (3)
You disclose that the net adjustment to Sales of $75 million is required to reflect the total sales that Organon will record for product manufactured and sold to Merck at the price expected to be provided for the manufacturing and supply agreements to be entered into in conjunction with the Separation. You also include a corresponding pro forma adjustment for Cost of Sales.
Rest of the question

Please clarify whether these adjustments represent actual inventory transfers to Merck during the year ended December 31, 2020 adjusted to reflect the pricing terms set forth in the manufacturing and supply agreements.

OGN answered

No reply letter found.

SEC letter of Apr 20, 2021 ↗ no reply letter on EDGAR
Amendment to Form 10-12B · Notes to Combined Financial Statements
SEC asked
Subsequent Events, page F-38 1. We note your disclosure on page 24 that in March 2021 Merck announced the signing of a definitive agreement for you to acquire Alydia Health, which is a commercial-stage medical device company. Please revise your discussion of subsequent events to disclose this transaction. Please also tell us whether this transaction has an impact on your pro forma financial information.
Rest of the question

In this regard, we note that a Merck news release dated March 30, 2021 indicates that a portion of the acquisition consideration will be paid prior to completion of the spin-off.

OGN answered

No reply letter found.

Form 10

2020-11-29 to 2020-11-29 · 16 questions · 1 letter from the SEC, 0 from the company
No closing letter
AcquisitionsRisk factorsResults discussion (MD&A)Income taxesLegal and contingenciesGoodwill and impairmentCritical estimatesLiquidity and cashRevenue
SEC letter of Nov 29, 2020 ↗ no reply letter on EDGAR
Exhibit 99.1 Information Statement · Industry, Ranking and Market Data, page ii
SEC asked (1)
Your statement that you have not independently verified third-party market and industry data may imply an inappropriate disclaimer of responsibility with respect third-party information included in your registration statement. Please either delete this statement or specifically state that you are liable for such information.
OGN answered

No reply letter found.

Company Overview, page 7
SEC asked (2)
We note your disclosure that the sizeable impacts of loss of exclusivity for many of your products have passed and that you expect your portfolio will continue to deliver strong, reliable operating profit. Please revise to disclose which of your material products no longer have patent protection and when related market exclusivity ended.
Rest of the question

To the extent practicable, please quantify the impacts of loss of exclusivity and disclose when the material impacts to your sales occurred.

OGN answered

No reply letter found.

Company Overview, page 7
SEC asked (3)
We note your market statistics for the global market for biosimilars and the estimate of the aggregate market value of biologics that will lose patent protection in the next decade. Please balance this disclosure with disclosure of the current size of the markets for your existing biosimilars and make it clear that you do not currently have product candidates that address the broad market of biologic products that
Rest of the question

will lose patent protection in the next decade. Additionally, we note your disclosure on page 10 that you believe your biosimilars exhibit substantial early stage growth potential. Please revise this statement and similar statements throughout your registration statement to remove any implication that you will be successful in securing any particular market share. As examples only, we note your disclosure on page 83 that you believe you are poised to capture significant market share within a large but untapped biosimilars market, and on page 84 that you believe your are poised to continue the initial success "[you] have realized to date." Where you discuss your established brands market and strategy beginning on page 86, revise to briefly explain what you mean by direct product promotion to capture an improved operating leverage position and potential growth and further investment in selling models that strengthen your portfolio and in digital omni-channel selling capabilities.

OGN answered

No reply letter found.

Summary of Risks Related to Organon's Business and the Separation, page 14
SEC asked (4)
Please add a bullet point that highlights the risks related to your indebtedness that you expect to incur to finance the cash distribution to Merck, as discussed on page 35. Please also highlight under an appropriate heading your dependence on your collaboration with Samsung Bioepis for the development of biosimilars, as discussed on page 31.
Rest of the question

Risk Factors We expect to have limited in-house research and development capabilities and will rely on future acquisitions, partnerships..., page 23

OGN answered

No reply letter found.

Summary of Risks Related to Organon's Business and the Separation, page 14
SEC asked (5)
Please clarify the limitations on the intellectual property licenses for Nexplanon / Implanon NXT. Potential indemnification liabilities to Merck pursuant to the separation agreement could adversely affect us...., page 33
OGN answered

No reply letter found.

Summary of Risks Related to Organon's Business and the Separation, page 14
SEC asked (6)
Please expand your disclosure to discuss any pending material litigation for which you have agreed to indemnify Merck. There could be significant income tax liability if the Spin-off or certain related transactions are determined to be taxable..., page 33
OGN answered

No reply letter found.

Summary of Risks Related to Organon's Business and the Separation, page 14
SEC asked (7)
Please expand this risk factor to disclose the liabilities that Organon would incur if the spin-off is determined to be taxable.
OGN answered

No reply letter found.

Critical Accounting Estimates · Impairments of Long-Lived Assets, page 68
SEC asked (8)
Please tell us and expand the disclosure to indicate the nature and origin of the goodwill and intangible asset balances reported. Disclose the methodology used to determine the goodwill and intangible assets balances attributable to the carve-out business.
Rest of the question

Tell us if any of your reporting units can be considered to be at risk as defined in ASC 350 (i.e., fair value is not substantially in excess of the carrying value), and tell us the magnitude of the excess of the fair value over carrying value at your last testing date. Refer to the effects of the COVID-19 pandemic as necessary in your response. To the extent your reporting units are not at risk of failing the quantitative goodwill impairment test, please disclose this fact.

OGN answered

No reply letter found.

Our Biosimilars Products, page 84
SEC asked (9)
We note the table on page 84 that includes the global sales for the biologics comparable to your biosimilars. Please revise your presentation to make clear, if true, that the expected sales figures for your biosimilar products will be less than the global sales listed in the table for the commercialized biologics.
OGN answered

No reply letter found.

Our Biosimilars Products, page 84
SEC asked (10)
We note that your collaboration partner reached settlement agreements with AbbVie and and Roche in order for you to launch Hadlima and Ontruzant, respectively. Please explain the need for the settlement agreements and any limitations on your ability to commercialize these products.
OGN answered

No reply letter found.

Intellectual Property, page 92
SEC asked (11)
With respect to your material patents, please disclose the specific products, product groups and technologies to which such patents relate, whether they are owned or licensed, the type of patent protection you have, the expiration dates, the applicable jurisdictions and whether there are any contested proceedings or third-party claims.
OGN answered

No reply letter found.

Samsung Bioepis Development and Commercialization Agreement, page 109
SEC asked (12)
Please disclose the aggregate future milestone payments to be paid pursuant to the Samsung Bioepis agreement and any royalty rates or royalty range not to exceed ten percent, term and termination provisions. Please also file the agreement as an exhibit or tell us why you believe such filing is not required.
OGN answered

No reply letter found.

Combined Financial Statement of Organon & Co · Combined Statement of Equity, page F-5
SEC asked (13)
Please reconcile the Net transfers to Parent amounts presented on the Combined Statement of Equity on page F-5 to the amounts presented on the Combined Statement of Cash Flows on page F-6 for all periods presented.
OGN answered

No reply letter found.

Note 2. Basis of Presentation, page F-7
SEC asked (14)
We acknowledge your disclosure that explains that your financial statements have been prepared on a standalone basis, and were derived from Merck’s consolidated financial statements and accounting records. In addition, please include a statement, if true, that the assets, liabilities, revenue and expenses directly attributable to your operations have been reflected in your financial statements on a historical cost
Rest of the question

basis, as included in the consolidated financial statements of Merck. Please refer to ASC 805-50-30-5 and 30-6 as applicable in your response.

OGN answered

No reply letter found.

Note 2. Basis of Presentation, page F-7
SEC asked (15)
Please include a statement, if true, that the accounting policies of the carve-out business reflect the historical accounting policies applied by the parent entity, Merck, or include disclosure that clarifies any departure.
Rest of the question

If the preparation of carve-out financial statements resulted in adoption of an accounting principle or a change in accounting principle, please disclose that fact, and explain why the adoption was considered appropriate. Please refer to ASC 250-10-45-1 and 45-2 in your response.

OGN answered

No reply letter found.

Exhibits
SEC asked (16)
Please file the transition services agreement, manufacturing and supply agreement, trademark assignment and license agreement and intellectual property license agreement as exhibits to your registration statement on Form 10, or tell us why you believe these agreements are not required to be filed as exhibits.
OGN answered

No reply letter found.

Letters without questions

Other letters

UPLOAD and CORRESP
1 other letter: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 9 letters filed since 2020-11-30. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OGN/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.